Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 7: Hot Topics

Session Chair(s)

Arthur A. Levin, PhD

Arthur A. Levin, PhD

Distinguished Scientist, Avidity Biosciences, United States

The hot topics session is designed to provide the attendees with a glimpse at future oligonucleotide therapeutics. This session is a chance to see how the field is developing and what kind of novel approaches or applications are being studied in academia and industry. With this early look at these approaches, it is hoped that the audience can envision the promise of new technologies and have a preview of the kind of challenges these technologies will face or pose to the current regulatory environment.

Speaker(s)

Robert  Ward

Robert Ward

Chairman and CEO, Eloxx Pharmaceuticals, United States

Speaker

Jennifer  Panagoulias, RAC

Jennifer Panagoulias, RAC

Regulatory Affairs and Compliance Consultant, Consultant, United States

Experience with FDA’s Complex Innovative Design (CID) Pilot

Charles R Allerson, PhD

Charles R Allerson, PhD

VP of Chemistry and Drug Development, DTx Pharma, Inc., United States

Chantal  Ferguson

Chantal Ferguson

MD/PhD Candidate, University of Massachusetts Medical School, United States

Potent siRNA Silencing in the Brain

Daniele  Merico

Daniele Merico

Director of Molecular Genetics, Deep Genomics Inc., Canada

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.